The posting, in Summit Therapeutics's own words
archived Oct 24, 2026About Summit:
Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland. Overview of Role: Summit Therapeutics is seeking a dynamic and strategic Associate Director of Patient Engagement and Advocacy to support the development, implementation, and continuous improvement of patient engagement and advocacy strategies for ivonescimab across oncology indications including bladder, breast and gynecological cancer. This role will help ensure that patient perspectives are appropriately considered in Medical Affairs planning, clinical trial awareness, patient education, and external stakeholder engagement. The Associate Director will collaborate cross-functionally with Medical Affairs, Clinical Development, Clinical Operations, Market Access, Commercial, Regulatory, Compliance, Medical Communications, and external partners to support compliant, patient-centered programs aligned with Summit’s scientific, clinical, and business objectives. The ideal candidate will bring experience in patient advocacy, oncology, stakeholder engagement, and project management, with the ability to operate effectively in a fast-paced, collaborative, and launch-oriented environment.